SCHEMBL6718671

SCHEMBL6718671

CS(=O)(=O)c1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(Cl)c(Cl)c2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.43
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
MAPK14 Q16539 4/20 0.36
MAPK13 O15264 1/20 0.36
RAF1 P04049 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
CYP3A4 P08684 2/20 0.36
PTGS1 P23219 3/20 0.35
PTGS2 P35354 3/20 0.35
TRPV1 Q8NER1 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
TGFBR1 P36897 1/20 0.35
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726312 0.89 PTGS1 (0.46) BRAFESR1ESR2MAPK14MAPK13
SCHEMBL6723894 0.89 ESR1 (0.40) BRAFESR1ESR2MAPK14CYP3A4
SCHEMBL6720129 0.89 PTGS2 (0.43) BRAFLMNANPSR1ESR1ESR2
SCHEMBL6725841 0.89 PTGS2 (0.44) BRAFLMNANPSR1ESR1ESR2
SCHEMBL6730003 0.89 ESR1 (0.41) BRAFESR1ESR2MAPK14CYP3A4
SCHEMBL6735517 0.88 ESR1 (0.39) BRAFLMNANPSR1ESR1ESR2
SCHEMBL6729038 0.87 TGFBR1 (0.43) BRAFESR1ESR2MAPK14MAPK13
SCHEMBL6733692 0.87 SCN9A (0.38) BRAFLMNANPSR1ESR1ESR2
SCHEMBL6718891 0.87 PTGS2 (0.43) BRAFESR1ESR2MAPK14CYP3A4
SCHEMBL6723168 0.86 ESR1 (0.41) BRAFESR1ESR2MAPK14MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 BRAF 788/4885LMNA 4037/4885NPSR1 641/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 BRAF 935/4885LMNA 4107/4885NPSR1 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.